BetaEntity Annotation Prototype
← Back to diseases

Annotated abstract

Alzheimer’s drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal

bmj · 2026-03-20 · canonical JSON source

2 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

NHS watchdogs will re-evaluate their decision not to fund two new Alzheimer’s treatments on the health service after appeals from the drugs’ manufacturers.